中信证券：医药板块上涨主升浪有望中长期持续

Core Viewpoint - The pharmaceutical market in A-shares and Hong Kong is expected to see a significant recovery in the first half of 2025, driven by substantial optimization in medical insurance policies, strong recovery in hospital internal demand, and returns from innovation [1] Summary by Categories Market Performance - The performance improvement in the pharmaceutical sector during the first half of the year has not been fully reflected in valuations, despite the overall sector rising to 72% of its 5-year valuation percentile [1] Future Outlook - Given the major changes from the industrial support side to insurance payment side, the upward trend in the A-share and Hong Kong pharmaceutical sectors is far from over, with the main upward wave expected to continue in the medium to long term [1] Investment Strategy - The company recommends focusing on three areas for investment in the second half of the year: innovation-driven growth, internationalization combined with self-sufficiency, and reforms in out-of-hospital marketing models, particularly emphasizing leading companies with strong domestic demand certainty [1]